Identification of alternative DNA damage response genes to target in cancer could be useful as therapies in their own right and also in cases where tumours become resistant to other therapies, such as is currently observed in BRCA-deficient tumours treated with PARP inhibitors [90,91]. This evidence concerns the gene PARP1 and cancer.